RxDoctor Payments Data

Chuba Ononye, MD

Internal Medicine · Mesa, AZNPI 1629026018

Payments from drug & device makers

$406in general payments, 2019–2025

Across 16 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$149
  • AstraZeneca$122
  • Bardy Diagnostics, Inc.$29
  • Almatica Pharma LLC$21
  • AbbVie$18
  • Nevro Corp.$14
  • plus $52 from 4 others

What the payments were for

  • Food & beverage$406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk6$149
AstraZeneca1$122
Bardy Diagnostics, Inc.2$29
Almatica Pharma LLC1$21
AbbVie1$18
Nevro Corp.1$14
Medtronic1$14
Lilly USA, LLC1$14
Amgen1$12
Novartis1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406 in reported general payments places this provider in the 65th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$84,800
Medicare patients
148
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$45,958
EliquisApixaban32$35,703
TrulicityDulaglutide11$17,354
XareltoRivaroxaban19$17,093
RybelsusSemaglutide11$12,010
FarxigaDapagliflozin Propanediol12$6,575
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,066
Gabapentin94$2,607
Valsartan52$1,760
Levothyroxine Sodium139$1,501
Gemfibrozil35$1,294
Fenofibrate43$1,290
Ezetimibe42$1,233
Lisinopril195$1,128
Simvastatin119$1,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$149$57,96845 claims
Lilly USA, LLCTrulicity$14$17,35411 claims
AstraZenecaFarxiga$122$6,57512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →